**Core tip:** This is a retrospective study to evaluate the efficacy of standard treatment methods (*i.e*., palliative chemotherapy, palliative gastrectomy, and the best supportive care) in gastric cancer patients with peritoneal metastases (PM). Analysis was performed on 200 patients with synchronous PM. Palliative gastrectomy could prove effective in treating patients with early stage PM. The three standard treatment methods are equally effective for moderate stages of PM. In cases with advanced peritoneal carcinomatosis, a significant increase in prognosis was registered only after treatment with palliative chemotherapy.

INTRODUCTION
============

Gastric cancer (GC) continues to be one of the leading types of malignancies worldwide despite an ongoing decrease in incidence. It is the fifth most common type of cancer in the world and the third leading cause of cancer-related deaths\[[@B1]\]. The peritoneum is the most frequent site where metastases occur and is also the first site of recurrence after radical surgery in 60% of all recurrences\[[@B2],[@B3]\]. Peritoneal metastases (PM) are associated with poor prognosis -- the median overall survival (OS) is 3--4 mo\[[@B4],[@B5]\], with no survival at the 5th year after primary tumor resection\[[@B6]\].

To date, GC patients with PM have been treated using standard methods, such as palliative chemotherapy, palliative gastrectomy, or the best supportive care.

Systemic palliative chemotherapy in patients with intraperitoneally-disseminated GC is characterized by low efficiency and a minor increase in OS to nearly 8 mo\[[@B5],[@B7]\].

Detection of PM in patients with GC during medical intervention is regarded by most surgeons as an absolute contraindication to resection surgery in full volume. This decision is based on negative results from retrospective and randomized trials\[[@B8],[@B9]\]. At present, however, palliative surgery is being increasingly used in view of its efficiency in GC patients in the early stages of peritoneal carcinomatosis\[[@B10],[@B11]\].

In oncological practice today, the following new active multimodal methods of combined treatment are frequently applied in GC patients with PM: Hyperthermic intraperitoneal chemotherapy (HIPEC)\[[@B12]\], early postoperative intraperitoneal chemotherapy\[[@B13]\], pressured intraperitoneal chemotherapy\[[@B14]\], neoadjuvant intraperitoneal chemotherapy\[[@B15]\], and repeated intraperitoneal chemotherapy\[[@B16]\], among others. The application of these advanced methods of combined treatment makes it important to study the results of standard treatment for such patients in order to perform a comparative analysis of strategies. The vast majority of medical publications on this topic are focused on a broad category of patients suffering from disseminated GC with metastases of different forms, whereas very few publications highlight separate studies on the efficiency of standard treatment methods for specific GC patient groups with PM\[[@B4]\].

The objective of this study was to investigate the results of palliative chemotherapy, palliative gastrectomy, and the best supportive care for GC patients with synchronous PM based on the stage of peritoneal carcinomatosis in compliance with the Japanese Gastric Cancer Association (JGCA) classification\[[@B17]\] and the peritoneal cancer index (PCI)\[[@B18]\]. The end goal was to generate objective data for comparative analysis in subsequent studies of new combined treatments.

MATERIALS AND METHODS
=====================

Patients and specimens
----------------------

A retrospective treatment analysis was performed on 200 GC patients with synchronous peritoneal metastases. All patients received inpatient treatment at the Clinic of Oncology and Medical Radiology at the Danylo Halytsky Lviv National Medical University on the basis of the Lviv Oncology Regional Treatment and Diagnostic Center from 2008 to 2017. As part of the study, we made an analysis of clinical and morphological prognostic factors and evaluated the efficiency of standard treatment methods (*i.e*., palliative chemotherapy, palliative sub- or total gastrectomy, and the best supportive care) based on indicators of PM dissemination rate, namely PCI and stage of peritoneal carcinomatosis according to JGCA.

Ages of the patients under study ranged from 30 years to 87 years, with a median age of 59.5 ± 7.9 years. The diagnosis of GC in all patients was verified morphologically prior to treatment onset. The GC study was conducted based on criteria from the TNM 7^th^ edition classification (2009). The primary clinical and pathological features of patients are presented in Table [1](#T1){ref-type="table"}.

###### 

Clinical and pathological features of 200 intraperitoneally-disseminated gastric cancer patients

  **Characteristic**                                                               ***n* (%)**   
  -------------------------------------------------------------------------------- ------------- ------------
  Sex                                                                              Male          121 (60.5)
  Female                                                                           79 (39.5)     
  Primary gastric cancer location                                                  Antral part   56 (28)
  Corpus                                                                           44 (22)       
  Proximal part                                                                    7 (3.5)       
  Antral part + corpus                                                             34 (17)       
  Corpus + proximal part                                                           12 (6)        
  Subtotal or total lesion                                                         47 (23.5)     
  Borrmann's type                                                                  Type I        3 (1.5)
  Type II                                                                          19 (9.5)      
  Type III                                                                         106 (53)      
  Type IV                                                                          72 (36)       
  Tumor histology                                                                  G1            5 (2.5)
  G2                                                                               12 (6)        
  G3                                                                               54 (27)       
  G4                                                                               98 (49)       
  Signet ring cell                                                                 24 (12)       
  Mucinous                                                                         3 (1.5)       
  Unknown                                                                          4 (2)         
  Stage of peritoneal carcinomatosis according to Japanese classification (JGCA)   Р0 (Cyt+)     4 (2)
  Р1                                                                               46 (23)       
  Р2                                                                               40 (20)       
  Р3                                                                               110 (55)      
  PCI, points \[Median = 13 (0-37)\]                                               0 (Cyt+)      4 (2)
  1-6                                                                              64 (32)       
  7-12                                                                             25 (12.5)     
  13 and more                                                                      104 (52)      
  Unknown                                                                          3 (1.5)       
  Ascites                                                                          Present       87 (43.5)
  Absent                                                                           113 (56.5)    
  Extraperitoneal metastases                                                       Present       34 (17)
  Absent                                                                           166 (83)      
  Site of extraperitoneal metastases                                               Liver         10 (29)
  Non-regional lymph node                                                          16 (47)       
  Pleura                                                                           4 (12)        
  Lung + non-regional lymph node                                                   2 (6)         
  Suprarenal gland                                                                 1 (3)         
  Bones                                                                            1 (3)         

JGCA: Japanese Gastric Cancer Association; PCI: Peritoneal cancer index.

Staging of peritoneal metastases in GC patients
-----------------------------------------------

Assessment of the extent of intraperitoneal metastatic dissemination and its staging was carried out using PCI and peritoneal carcinomatosis staging by JGCA. Staging was performed during diagnostic laparoscopy, attempted laparotomy, non-resectable, or resectable palliative surgery. In patients without surgical verification of the peritoneal cavity, peritoneal carcinomatosis was staged on the basis of data obtained from spiral computed tomography.

РСІ was calculated in the following way: The abdominal cavity was divided into 13 conditional pelvic-abdominal sections. In each section, we evaluated the degree of carcinomatosis based on the size of PM from 1 to 3 points. This was followed by a summation of the values acquired from all sections; thus, the maximum value of PCI was 39\[[@B18]\].

Another objective method of the peritoneal carcinomatosis evaluation in patients with GC is JGCA classification: P0 (CY1) means there is no implantation metastases on the peritoneum, but there are malignant cells in the washings from the peritoneum, P1 means single metastases in the upper floor of the abdomen (above colon), P2 means single metastases in all departments of the abdominal cavity, and P3 implies diffuse carcinomatosis of the abdominal cavity, including the presence of ascites\[[@B17]\].

Assessment of the residual intraperitoneal metastatic process after resectable palliative surgery was based on completeness of the cytoreduction score (CC), calculated as follows: CC-0 - macroscopic residual tumor lesions on the peritoneum after surgery were not found; CC-1 - residual PM of not more than 2.5 mm in diameter were detected; CC-2 - the size of residual nodules was larger than 2.5 mm\[[@B18]\].

Combined treatment
------------------

Two hundred patients with GC under this study received one treatment out of three modalities: Palliative chemotherapy, palliative gastrectomy (total or subtotal), or best supportive care. A detailed description of the treatment modalities applied to patients in this study is given in Table [2](#T2){ref-type="table"}.

###### 

Treatment methods of 200 intraperitoneally-disseminated gastric cancer patients

  **Treatment modality**                                                     ***n* (%)**   
  -------------------------------------------------------------------------- ------------- ------------
  BSC                                                                        Total         105 (52.5)
  Only BSC                                                                   31 (29.5)     
  Attempted or non-resectable palliative surgery + BSC                       74 (70.5)     
  Stage of peritoneal carcinomatosis according to JGCA                                     
  P0 (Cyt+)                                                                  0             
  P1                                                                         20 (19)       
  P2                                                                         23 (21.9)     
  P3                                                                         62 (59.1)     
  PCI                                                                                      
  0 (Cyt+)                                                                   0             
  1-6                                                                        31 (29.5)     
  7-12                                                                       13 (12.4)     
  13 +                                                                       60 (57.2)     
  Unknown                                                                    1 (0.9)       
  Palliative chemotherapy                                                    Total         51 (25.5)
  Only palliative chemotherapy                                               24 (47)       
  Attempted or non-resectable palliative surgery + palliative chemotherapy   27 (53)       
  Stage of peritoneal carcinomatosis according to JGCA                                     
  P0 (Cyt+)                                                                  0             
  P1                                                                         6 (11.8)      
  P2                                                                         9 (17.6)      
  P3                                                                         36 (70.6)     
  PCI                                                                                      
  0 (Cyt+)                                                                   0             
  1-6                                                                        9 (17.6)      
  7-12                                                                       8 (15.7)      
  13 +                                                                       32 (62.7)     
  Unknown                                                                    2 (4)         
  Chemotherapy regimen                                                                     
  CF                                                                         19 (37.2)     
  5-FU                                                                       11 (21.6)     
  CAF                                                                        10 (19.6)     
  XELOX                                                                      7 (13.7)      
  ECF                                                                        3 (5.9)       
  Tegafur                                                                    1 (2)         
  Palliative gastrectomy                                                     Total         44 (22)
  Only palliative gastrectomy                                                40 (91)       
  Palliative gastrectomy + palliative chemotherapy                           4 (9)         
  Stage of peritoneal carcinomatosis according to JGCA                                     
  P0 (Cyt+)                                                                  4 (9.1)       
  P1                                                                         20 (45.4)     
  P2                                                                         8 (18.2)      
  P3                                                                         12 (27.3)     
  PCI                                                                                      
  0 (Cyt+)                                                                   4 (9.1)       
  1-6                                                                        24 (54.5)     
  7-12                                                                       4 (9.1)       
  13 +                                                                       12 (27.3)     
  Lymph node dissection                                                                    
  D0, 1                                                                      35 (79.5)     
  D1+, 2                                                                     9 (20.5)      
  Completeness of cytoreduction score                                                      
  CC-0                                                                       9 (20.5)      
  CC-1                                                                       19 (43.2)     
  CC-2                                                                       16 (36.3)     

JGCA: Japanese Gastric Cancer Association; PCI: Peritoneal cancer index; CC: Completeness of cytoreduction; BSC: Best supportive care.

In the "best supportive care" and "palliative chemotherapy" groups, 49 patients underwent attempted (exploratory) laparotomy and biopsy, while 52 patients received non-resectable palliative surgery. The latter group underwent gastroenterostomy (43 patients, 82.9%), jejunostomy, cardia's stenting, and tumor perforation suturing of the stomach (2 patients each, 3.8% each), ileotransversostomy, sigmostomy, and stoppage of gastrointestinal bleeding (1 patient each, 1.9% each).

In 44 patients of the "palliative gastrectomy" group, the following procedures were performed: total gastrectomy in 19 patients (43.2%), distal subtotal gastrectomy in 21 patients (47.7%), and total gastrectomy with lower esophageal resection in 4 patients (9.1%). Of these 44 patients, macroscopically complete cytoreduction of peritoneal metastases was achieved in nine (20.5%): Four patients underwent palliative surgery with P0Cyt+ and five patients went through the removal of metastases implantation.

Follow-up
---------

After treatment was completed, all patients were followed up on a regular basis. We performed physical check-ups and ultrasonography of the abdominal cavity every 3 mo, as well as computerized tomography and chest radiography every 6 mo. The overall survival was measured from the date of surgery or the date of the other therapy onset to the date of death or the last follow-up examination.

Statistical analysis
--------------------

Statistical analysis of the primary data was performed using SPSS 22 and Statistical 6 software. The censored Kaplan-Meier method helped to evaluate the cumulative survival of patients, whereas the reliability of the survival difference in certain groups was determined using a log-rank coefficient. Multivariate analysis was performed using the Cox model, and Pearson's linear correlation coefficient allowed the determination of statistical correlations.

RESULTS
=======

The closest results
-------------------

Post-operative morbidity (Clavien-Dindo grade I-IV complications) developed in 15 patients (10.3%) after exploratory, palliative non-resectable, or palliative resectable surgery. The 60-d postoperative mortality rate was 3.5% (5 patients): 3 patients died after the palliative gastrectomy; 1 patient after gastroenterostomy as a result of surgical complications; and 1 patient after colostomy, due to complications of GC. Overall, complications from palliative chemotherapy were observed in 8 patients (14.5%).

Long-term outcomes
------------------

The median follow-up time for the study was 45.2 mo. The OS rate for 200 GC patients with PM, who underwent standard treatment, was 5.4 mo \[95% confidence interval (CI): 4.4--6.8\]. The 1-year survival rate was 18.4% (95%CI: 13.0--24.6). Results of the univariate analysis of prognostic factors are presented in Table [3](#T3){ref-type="table"}.

###### 

Univariate analysis of prognostic factors for 200 intraperitoneally-disseminated gastric cancer patients

                               ***n***   **1-yr survival, %**   **Median survival in mo**   ***P* value**
  ---------------------------- --------- ---------------------- --------------------------- ---------------
  Gender                                                                                    
  Male                         121       18.4                   5.2                         0.4
  Female                       79        18.5                   6.5                         
  Age                                                                                       
  \< 60                        100       21.1                   6.5                         0.26
  60+                          100       15.4                   5.0                         
  Borrmann's type                                                                           
  I-II                         22        34.3                   6.8                         0.13
  III-IV                       178       16.5                   5.2                         
  Ascites                                                                                   
  Absence                      113       29.5                   6.9                         \< 0.0001
  Presence                     87        1.7                    4.0                         
  Histology                                                                                 
  G1                           5         0                      3.6                         0.64
  G2                           12        40                     6.8                         
  G3                           54        13.5                   5.6                         
  G4                           98        21.2                   5.2                         
  Signet ring                  24        9.5                    6.5                         
  Mucinous                     3         0                      3.7                         
  Extraperitoneal metastases                                                                
  No                           165       19.7                   6.4                         0.031
  Yes                          34        7.7                    4.2                         
  JGCA classification                                                                       
  P0 (Cyt+)                    4         0                      4.0                         \< 0.0001
  P1                           46        47.2                   9.8                         
  P2                           40        18.8                   6.7                         
  P3                           110       5.1                    4.0                         
  PCI                                                                                       
  0 (Cyt+)                     4         0                      4.0                         \< 0.0001
  1-6                          64        39.8                   8.5                         
  7-12                         25        6.7                    4.2                         
  13+                          104       5.5                    4.1                         
  Lymph node dissection                                                                     
  D0, 1                        35        31.4                   7.5                         0.61
  D1+, 2                       9         50.0                   8.9                         
  Cytoreduction score                                                                       
  CC-0                         9         22.2                   7.5                         0.065
  CC-1                         19        58.2                   13.1                        
  CC-2                         16        18.8                   4.7                         

JGCA: Japanese Gastric Cancer Association; PCI: Peritoneal cancer index; CC: Completeness of cytoreduction.

By means of the univariate analysis, we discovered that the following factors significantly influenced patient survival: Presence of ascites, presence of extraperitoneal metastases, stage of PM according to JGCA (Figure [1](#F1){ref-type="fig"}), and PCI (Figure [2](#F2){ref-type="fig"}). However, there was no statistical difference between the prognosis of patients with PCI 7-12 and patients with PCI 13+ points (*P* = 0.45).

![Influence of stage of peritoneal carcinomatosis on overall survival of gastric cancer patients with peritoneal metastases. JGCA: Japanese Gastric Cancer Association.](WJGO-12-569-g001){#F1}

![Influence of peritoneal cancer index on overall survival of gastric cancer patients with peritoneal metastases.](WJGO-12-569-g002){#F2}

In multivariate analysis, the following factors retained their statistical significance: the presence of extraperitoneal metastases \[hazard ratio (HR) = 1.55, 95%CI: 0.95-2.42; *P* = 0.054\], the stage of PM according to JGCA (HR = 3.41, 95%CI: 2.19-5.29; *P* = 0, 0001), and the PCI (HR = 1.78, 95%CI: 1.05-3.01; *P* = 0.032). The presence of ascites lost their statistical significance (HR = 1.32, 95%CI: 0.80-2.20; *P* = 0.28).

Table [2](#T2){ref-type="table"} shows a clear tendency to perform palliative gastrectomy in patients with early stage PM, and to use palliative chemotherapy and best supportive care for patients with diffuse peritoneal carcinomatosis. In this regard, further analysis of the efficiency of standard therapies was performed in those groups of patients, who were grouped on the basis of peritoneal carcinomatosis stages (PCI index and JGCA classification of GC).

Prognostic value of the standard treatment methods depending on the stage of peritoneal carcinomatosis according to JGCA
------------------------------------------------------------------------------------------------------------------------

The median OS of 46 GC patients with P1 carcinomatosis was 9.8 mo (95%CI: 6.9-17.0), 1-year survival rate was 47.2% (95%CI: 31.9-61.1), and 2-year survival was 15.7% (95%CI: 6.5-28.9). Patients with extraperitoneal metastases had a median survival rate of 3.9 mo compared to 12.4 mo for patients without extraperitoneal metastases (*P* = 0.0001). Treatment with palliative gastrectomy resulted in a probable increase in survival compared to the conservative treatment approach (Table [4](#T4){ref-type="table"}).

###### 

Efficiency of standard treatment methods, depending on stage of peritoneal carcinomatosis according to the Japanese Gastric Cancer Association

                                                           ***n***   **1-yr survival, %**   **Median survival in mo**   ***P* value**
  -------------------------------------------------------- --------- ---------------------- --------------------------- ---------------
  P1                                                                                                                    
  BSC                                                      20        38.5                   8.5                         0.12
  Palliative chemotherapy                                  6         33.3                   6.7                         
  Palliative gastrectomy                                   20        61.1                   17                          
  BSC                                                      20        38.5                   8.5                         0.71
  Palliative chemotherapy                                  6         33.3                   6.7                         
  BSC                                                      20        38.5                   8.5                         0.032
  Palliative gastrectomy                                   20        61.1                   17                          
  Conservative approach of BSC + palliative chemotherapy   26        37.5                   7.8                         0.05
  Palliative gastrectomy                                   20        61.1                   17                          
  P2                                                                                                                    
  BSC                                                      23        11.7                   5                           0.56
  Palliative chemotherapy                                  9         22.2                   8.4                         
  Palliative gastrectomy                                   8         37.5                   7.5                         
  P3                                                                                                                    
  BSC                                                      62        2.3                    3.2                         0.003
  Palliative chemotherapy                                  36        7.8                    5.6                         
  Palliative gastrectomy                                   12        8.3                    4.7                         
  BSC                                                      62        2.3                    3.2                         0.2
  Palliative gastrectomy                                   12        8.3                    4.7                         
  BSC                                                      62        2.3                    3.2                         0.0006
  Palliative chemotherapy                                  36        7.8                    5.6                         

BSC: Best supportive care.

The median OS of 40 GC patients with P2 carcinomatosis was 6.7 mo (95%CI: 4.3-8.4) and 1-year survival rate was 18.8% (95%CI: 7.8-33.5). Results of the standard treatment methods comparison did not show a statistical difference.

The median OS of 110 GC patients with P3 carcinomatosis was 4.0 mo (95%CI: 3.4-4.7) and 1-year survival rate was 5.1% (95%CI: 1.7-11.3). Only palliative chemotherapy showed a statistically probable increase in survival compared to best supportive care.

Prognostic value of standard treatment methods depending on PCI
---------------------------------------------------------------

The median OS of 64 GC patients with PCI 1-6 points was 8.5 mo (95%CI: 7.5-12.4), 1-year survival rate was 39.8% (95%CI: 27.6-51.8), and 2-year survival rate was 12.7% (95%CI: 5.6-22.7). Patients with extraperitoneal metastases had a 1-year survival rate of 16.7% (95%CI: 0.7-51.7) compared to 41.2% (95%CI: 28.1-53.9) for patients without extraperitoneal metastases (*P* = 0.012). Patients who were classified as P1 in JGCA with a PCI of 1-6 points had a 1-year survival rate of 47.2% (95%CI: 31.9-61.1) compared to 22.2% (95%CI: 6.9-42.9) for P2 patients (*P* = 0.042). The use of palliative gastrectomy led to a probable increase in survival compared to the conservative treatment approach (Table [5](#T5){ref-type="table"}).

###### 

Efficiency of standard treatment methods based on peritoneal cancer index level

                                                           ***n***   **1-year survival, %**   **Median survival, mo**   ***P* value**
  -------------------------------------------------------- --------- ------------------------ ------------------------- ---------------
  PCI 1-6                                                                                                               
  BSC                                                      31        30.8                     8.3                       0.089
  Palliative chemotherapy                                  9         33.3                     6.9                       
  Palliative gastrectomy                                   24        54.5                     12.6                      
  BSC                                                      31        30.8                     8.3                       0.94
  Palliative chemotherapy                                  9         33.3                     6.9                       
  BSC                                                      31        30.8                     8.3                       0.045
  Palliative gastrectomy                                   24        54.5                     12.6                      
  Conservative approach of BSC + palliative chemotherapy   40        31.5                     8.0                       0.03
  Palliative gastrectomy                                   24        54.5                     12.6                      
  D0,1 lymph node dissection                               18        52.9                     12.6                      0.91
  D1+, 2 lymph node dissection                             6         60.0                     17.0                      
  PCI 7-12                                                                                                              
  BSC                                                      13        0                        2.1                       0.082
  Palliative chemotherapy                                  8         0                        4.3                       
  Palliative gastrectomy                                   4         50.0                     4.2                       
  PCI 13+                                                                                                               
  BSC                                                      60        2.5                      3.4                       0.004
  Palliative chemotherapy                                  32        8.9                      6.0                       
  Palliative gastrectomy                                   12        8.3                      4.7                       
  BSC                                                      60        2.5                      3.4                       0.26
  Palliative gastrectomy                                   12        8.3                      4.7                       
  BSC                                                      60        2.5                      3.4                       0.0008
  Palliative chemotherapy                                  32        8.9                      6.0                       

PCI: Peritoneal cancer index; BSC: Best supportive care.

The median OS of 25 GC patients with PCI 7-12 points was 4.2 mo (95%CI: 2.1-5.5) and 1-year survival was 6.7% (95%CI: 0.49-25.2). Comparison of standard treatment methods did not show a statistically probable difference.

The median OS of 104 GC patients with PCI 13+ points was 4.1 mo (95%CI: 3.6-5.2), with a 1-year survival of 5.5% (95%CI: 1.9-12.2). Only palliative chemotherapy showed a statistically probable increase in survival rate compared to the best supportive care.

DISCUSSION
==========

In view of a large clinical study currently being conducted to evaluate aggressive multimodal therapeutic approaches to treating GC patients, there is a need to have additional knowledge of the natural history of GC with PM. The results of our study confirmed an extremely poor prognosis (median OS of 5.4 mo) in GC patients, which depends on the extent of PM dissemination, as previously reported. Thus, the French multicenter study EVOCAPE1 demonstrated that the median OS of GC patients with sporadic PM was 7.9 mo, whereas it was 1.9 mo in those with diffuse peritoneal carcinomatosis\[[@B4]\]. Our study also discovered a probable prognosis dependence on the extent of PM dissemination. Thus, patients with early stage PM (according to JGCA) had an OS of 9.8 mo, whereas patients with diffuse peritoneal carcinomatosis had an OS of only 4 mo.

Research on HIPEC efficiency for GC patients, as previously reported, shows that prognosis is directly dependent on the level of PCI\[[@B19]\]. However, our study of standard treatment methods does not show any significant difference in the survival of patients with PCI of 7-12 points *vs* those with PCI of 13 or more. Long-term survival was observed only in patients with PCI of 1-6 points; median OS was 8.2 mo *vs* 4.1 mo in patients with PCI \> 6. Similar unexpected results were obtained in other reports\[[@B20]\].

Discussion of the reasonability of palliative surgery in the resection volume of patients with intraperitoneally-disseminated GC remains open. Thus, in a randomized REGATTA trial\[[@B8]\], the use of gastrectomy with systemic palliative chemotherapy did not result in a significant survival advantage over chemotherapy alone. However, according to a number of retrospective studies, palliative gastrectomy feasibly increases the survival in patients at early stages of PM (P1, P2 dissemination according to JGCA), but at the same time does not affect the prognosis of patients with diffuse peritoneal carcinomatosis (P3 dissemination)\[[@B10],[@B11],[@B21]\]. In addition, according to recent data, survival rates in patients with good responsiveness to initial chemotherapy increase after subsequent palliative gastrectomy (conversion surgery)\[[@B22]\].

The results of our study also indicate a significant increase in survival after palliative gastrectomy in patients with early stage PM (Figure [3](#F3){ref-type="fig"}). Thus, at P1 stage of carcinomatosis (JGCA), a double increase in the median survival rate was recorded compared to the conservative approach (7.8-17 mo). In patients with PCI of 1-6 points, palliative gastrectomy also feasibly increased prognosis (8-12.6 mo). However, in patients with diffuse peritoneal carcinomatosis (P3, PCI \> 6), palliative gastrectomy did not increase survival rate, as expected.

![Influence of standard treatment methods on survival of gastric cancer patients with P1 carcinomatosis. JGCA: Japanese Gastric Cancer Association.](WJGO-12-569-g003){#F3}

The results of this study showed no probable influence on the survival of intraperitoneally-disseminated GC patients of lymph node dissection volume during palliative gastrectomy. Naturally, this is conditioned by the development of early intraperitoneal relapses, which determine prognosis to a large extent. Besides, there was no influence registered on the survival rate of such patients after complete cytoreduction (CC-0). This is obviously because intraperitoneal chemotherapy was not studied in the course of patient treatment. However, a number of studies on HIPEC efficiency demonstrated a probable influence of complete cytoreduction on survival rates\[[@B12],[@B19],[@B23]\].

The results of palliative chemotherapy application in this study are consistent with data from the literature, although the inefficiency of this method for patients with early stage PM requires further analysis.

In summary, the obtained results of standard treatment methods applied to GC patients with PM may form the basis for comparative analyses of the efficiencies of new combined therapies for such patients in subsequent studies.

GC patients with PM are characterized by extremely poor prognoses. In this study, long-term survivors were found in the group with PCI of 1-6 points with no survival difference in the group with PCI 7-12 *vs* the group with PCI 13+ points. Palliative gastrectomy could be an effective treatment method for patients with early stage PM. The three standard treatment methods are equally effective for moderate stages of PM. With advanced peritoneal carcinomatosis, a significant increase in prognosis is only recorded after palliative chemotherapy.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Peritoneal metastasis is the most common pattern of synchronous and metachronous dissemination of gastric cancer (GC). Such patients are characterized by poor prognoses. New therapeutic modalities are being increasingly employed. However, the results of existing standard treatment methods remain insufficiently reported in the literature.

Research motivation
-------------------

A large number of reports of results from modern methods of combined treatment of GC patients with peritoneal metastases (hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy, pressurized intraperitoneal aerosol chemotherapy, *etc*) are now available in the literature. Most of them relate to early stages of peritoneal carcinomatosis (according to classifications of the Japanese Gastric Cancer Association and peritoneal cancer index). However, medical publications on standard treatment topics are focused on a broad category of patients with intraperitoneally-disseminated GC or with metastases of different forms.

Research objectives
-------------------

To develop more advanced methods, it becomes necessary to study the results of existing standard treatment methods (*i.e*., palliative chemotherapy, palliative gastrectomy, and best supportive care) in patients with intraperitoneally-disseminated GC in order to perform a comparative analysis of strategies.

Research methods
----------------

A retrospective analysis of the efficiency of standard treatment methods was performed on 200 GC patients with synchronous peritoneal metastases.

Research results
----------------

The median overall survival and 1-year survival of patients with РCI of 1-6, 7-12, and 13+ points were 8.5 mo, 4.2 mo, and 4.1 mo, and 39.8%, 6.7%, and 5.5%, respectively. Long-term survivors were found in the group with PCI of 1-6 points and there was no survival difference in groups with PCI 7-12 *vs* PCI 13+ points. Palliative gastrectomy increased the median overall survival to 12.6 mo compared to conservative approach of 8.0 mo in patients with РCI of 1-6 points. In patients with РCI 13+ points, only palliative chemotherapy increased the overall survival to 6.0 mo compared to 3.4 mo for best supportive care.

Research conclusions
--------------------

GC patients with peritoneal metastases are characterized by extremely poor prognoses. Palliative gastrectomy could prove effective in treating patients with early stage peritoneal metastases. The three standard treatment methods are equally effective for moderate stages of peritoneal metastases. In cases with far advanced peritoneal carcinomatosis, a significant increase in prognosis was registered only after treatment with palliative chemotherapy.

Research perspectives
---------------------

Generated objective data of the study could be used for comparative analysis in subsequent studies of new combined treatments.
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